Biogen trims guidance as growth drivers remain elusive

• Biogen (NASDAQ:BIIB) Q3 results:
• Revenues: $3,376M (-6%).
• Multiple sclerosis franchise revenue: $2,257M (-4%); Spinraza sales: $495M (-10%); biosimilars: $208M (+13%).
• Tecfidera sales down 15% to $953M.
• Net income: $702M (-55%); non-GAAP net income: $1,390M (-18%); EPS: $4.46 (-47%); non-GAAP EPS: $8.84 (-4%).
• 2020 guidance: Revenues: $13.2B - 13.4B from $13.8B - 14.2B; EPS: $25.50 - 26.50 from $32.00 - 34.00; non-GAAP EPS: $32.50 - 33.50 from $34.00 - 36.00.
• https://seekingalpha.com/news/3624138-biogen-trims-guidance-growth-drivers-remain-elusive
  
•